Aviado · Research
Longevity Daily
Thursday, July 30, 2026
Listen
Today's Brief
Today's strongest thread is chronic inflammation—now recognized as a root cause, not just a symptom, of aging diseases like Alzheimer's, cancer, and diabetes—and the NYT Magazine's landmark investigation is required reading for anyone serious about longevity. On the cognitive front, a new blood test could detect Alzheimer's 20 years early, while Phase 3 EVOKE data delivers a sobering reality check on GLP-1 optimism in dementia. In supplements, Newsweek's peptide safety investigation and an honest evidence review cut through the hype. Bryan Johnson's autoimmune diagnosis rounds out the edition with an important lesson about the limits of obsessive optimization.
10 stories1 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Blood Test That Detects Alzheimer's 20 Years Early Is Heading Into Clinical Trials
A new blood test capable of identifying biological signs of Alzheimer's disease up to two decades before symptoms appear has been greenlit for clinical trials. If validated, early detection would give clinicians—and patients—a critical window for lifestyle interventions and emerging drug treatments before irreversible neurological damage occurs. This is the kind of diagnostic breakthrough that could fundamentally change how we approach cognitive aging, shifting the focus from treatment to prevention.
Read more →Semaglutide Fails Its Alzheimer's Phase 3 Trial—What the EVOKE Data Really Means
Despite real-world evidence that semaglutide cut first-time Alzheimer's diagnoses by 40–70% in over a million diabetes patients, the rigorous Phase 3 EVOKE trial found no significant cognitive benefit. The trial used gold-standard endpoints—MRI, cerebrospinal fluid biomarkers, and cognitive composites—making the null result difficult to explain away. For anyone following the GLP-1-for-brain narrative, this is a critical data point: observational associations and clinical trial results are two very different things.
Read more →Intermittent CO2 Exposure May Boost the Brain's Waste-Clearance System
Researchers found that intermittently elevating CO2 levels can stimulate glymphatic drainage—the brain's primary system for removing toxic protein aggregates like amyloid and tau that drive neurodegeneration. Glymphatic function declines significantly with age, and this approach (manipulating gas concentrations that affect blood vessel dilation) restored cerebrospinal fluid flow in early experiments. The results are preliminary and require human validation, but they point to a novel non-pharmacological lever for supporting long-term brain health.
Read more →Supplements & Compounds
Peptides Are the New Longevity Craze. The Safety Data Tells a Different Story
The latest obsession in the $6.8 trillion wellness industry—injectable and oral peptides—is drawing sharp warnings from scientists who say health scares are accumulating while long-term human safety data remains dangerously thin. Enthusiasm is far outrunning the evidence, with many compounds being used off-label without rigorous clinical trial support. If you're currently taking—or considering—peptides as part of a longevity protocol, Newsweek's investigation is essential reading before your next order.
Read more →Which Supplements Actually Work? An Honest Evidence Review
A rigorous evidence review cuts through supplement marketing to identify where the science genuinely supports use: fish oil helps most if you rarely eat fish, and correcting proven deficiencies in vitamin D, B12, or iron makes a real difference. For well-nourished adults without documented deficiencies, most supplements deliver minimal benefit—and some carry real risk. The practical takeaway: test for deficiencies first, then supplement strategically, rather than defaulting to a stack of hopeful daily pills.
Read more →Research & Papers
Chronic Inflammation Is Not Just a Symptom—It May Be Causing Your Aging Diseases
The New York Times Magazine publishes what may be the most important mainstream longevity story of the year: mounting evidence that chronic inflammation doesn't just accompany aging diseases like diabetes, cancer, and Alzheimer's—it actively drives them. As the immune system progressively misfires with age, producing a state researchers call 'inflammaging,' this low-grade systemic fire quietly damages tissues for years before disease manifests. The mechanisms are becoming clear enough that researchers believe anti-inflammatory interventions—from diet and exercise to emerging drugs—could simultaneously reduce risk across multiple age-related conditions. This piece reframes what healthy aging actually means: taming the immune system may matter more than any single supplement or drug.
Read more →Scientists Crack the Metabolic Code Behind Senescent Cells' Inflammatory Damage
A new Nature study identifies a mitochondrial metabolic checkpoint that controls how much inflammatory signaling senescent cells unleash into surrounding tissue—the harmful secretory program known as SASP. The mechanism: a mitochondrial pyruvate-citrate-acetyl-CoA axis feeds histone acetylation at SASP genes, meaning cellular metabolism and epigenetics work in concert to amplify the inflammatory output of aging cells. In aged mice, blocking this pathway (by inhibiting SLC25A1, the mitochondrial citrate exporter) reduced systemic inflammation and improved healthspan—providing a precise new drug target for senolytic therapy development.
Read more →Aviado Research: Latest Analysis Now Available
Aviado Research's newest analysis delivers an evidence-based deep dive into the latest developments in longevity science, going beyond the headlines to provide rigorous, actionable context for what the research actually means. Our editorial team reviews the strongest signals from recent studies to help you separate genuine breakthroughs from noise.
Read the full Aviado analysis →Lifestyle & Nutrition
Bryan Johnson's Rare Diagnosis Reveals the Real Limits of Longevity Optimization
After years of spending $10 million+ on Project Blueprint and building a global platform around radical health optimization, Bryan Johnson disclosed a rare autoimmune gastritis diagnosis—and publicly questioned whether he's taken his longevity project too far. Strikingly, Johnson had flagged low ferritin for 11 years despite aggressive dietary and supplemental interventions, yet the condition went undetected by his otherwise comprehensive testing protocols. The case is a useful corrective: even the most comprehensively monitored body in the world can harbor conditions no biomarker stack can prevent—and obsessive tracking may surface anxiety as readily as it surfaces disease.
Read more →9 Things Longevity Experts Wish You'd Start Doing in Midlife
A New York Times report compiles expert guidance on the highest-yield health interventions to prioritize during your 40s and 50s—the decade that most determines your healthspan trajectory. The headline finding: while aerobic fitness remains essential, research is increasingly showing that muscle strength may be equally important for living well into old age. Think of this as a practical checklist from cardiologists, exercise scientists, and geriatricians for the interventions that deliver the biggest returns when started before the decline begins.
Read more →